Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CHOEP-14 + Rituximab With CNS Prophylaxis in Patients Less Than 65 Years With Diffuse Large B-Cell Lymphoma/Follicular Lymphoma Grade III, Stage II-IV With Risk Factors (Age Adjusted IPI) >=2. A Phase II Study

Next Previous
X
Search
Trial Profile

CHOEP-14 + Rituximab With CNS Prophylaxis in Patients Less Than 65 Years With Diffuse Large B-Cell Lymphoma/Follicular Lymphoma Grade III, Stage II-IV With Risk Factors (Age Adjusted IPI) >=2. A Phase II Study

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 07 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rituximab (Primary) ; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Methotrexate; Pegfilgrastim; Prednisone; Vincristine
  • Indications B-cell lymphoma; Diffuse large B cell lymphoma
  • Focus Therapeutic Use
  • Acronyms CRY-04

    • Most Recent Events

    • 06 Nov 2019 Results (n=96) of two clinical studies: a phase 2 trial- dose-dense chemoimmunotherapy (NCT01502982) and a early systemic CNS prophylaxis with high-dose methotrexate study- (CHIC or NCT01325194), assessing clinical feasibility and prognostic value of ctDNA in prospectively collected samples from high risk B-cell lymphoma patients, released in 61st Annual Meeting and Exposition of the American Society of Hematology
    • 04 Dec 2018 Results analysing data from the Nordic Lymphoma Group CRY-04 and Chic trials to compare clinical outcome and biological prognostic factors in patients treated with CNS prophylaxis given in the beginning (CHIC) versus at the end (CRY-04) of therapy presented at the 60th Annual Meeting and Exposition of the American Society of Hematology
    • 07 Jan 2012 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top